The successful transplantation of the Company's proprietary RPE cells in the last patient of twelve represents the completion of the enrollment stage of this trial. The trial is a prospective, open-label study designed to determine the safety and tolerability of the Company's RPE cell therapy following sub-retinal transplantation into patients.
http://www.hispanicbusiness.com/2014/9/25/advanced_cell_technology_announces_final_patient.htm
http://www.hispanicbusiness.com/2014/9/25/advanced_cell_technology_announces_final_patient.htm
No comments:
Post a Comment